Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress note on Japanese multicenter bromocriptine monotherapy

S Kuno1

  • 1Department of Neurology, Utano National Hospital, Kyoto, Japan.

European Neurology
|January 1, 1993
PubMed
Summary

Bromocriptine monotherapy for Parkinson's disease showed better outcomes than combination therapy. Patients on bromocriptine alone experienced less disease progression and no wearing-off phenomenon.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PP121. Expression of PlGF, sFlt, MTF-1, HO-1 and HIF-1 alpha mRNAs in preeclampsia placenta and effect of preeclampsia sera on their expression of choriocarcinoma cells.

Pregnancy hypertension·2015
Same author

Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease.

The Journal of international medical research·2012
Same author

Breakdown of dynamic balance of a particle in a quadrupole cell by laser-induced aerosol heating.

Applied optics·2010
Same author

Choline acetyltransferase from a temperature-sensitive mutant of caenorhabditis elegans.

Neurochemistry international·2010
Same author

ACTN3 polymorphism affects thigh muscle area.

International journal of sports medicine·2010
Same author

Effect of 12 weeks of moderate-intensity resistance training on arterial stiffness: a randomised controlled trial in women aged 32-59 years.

British journal of sports medicine·2008

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Parkinson's disease is a progressive neurodegenerative disorder.
  • Current treatments like levodopa can lead to motor complications.
  • Bromocriptine is a dopamine agonist with potential neuroprotective properties.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of bromocriptine monotherapy versus bromocriptine-levodopa combination therapy in Parkinson's disease.
  • To assess disease progression and the occurrence of the wearing-off phenomenon over six years.

Main Methods:

  • A nationwide multicenter collaborative study followed patients for six years.
  • 30 patients received bromocriptine monotherapy.
  • 66 patients received bromocriptine-levodopa combination therapy.

Main Results:

  • Disease severity increased in 20% of monotherapy patients vs. 45% in combination therapy patients.
  • The wearing-off phenomenon was absent in the bromocriptine monotherapy group.
  • 30% of combination therapy patients experienced the wearing-off phenomenon, linked to levodopa administration.

Conclusions:

  • Bromocriptine monotherapy demonstrates a favorable long-term outcome in Parkinson's disease.
  • Bromocriptine may possess a direct protective effect on substantia nigra neurons.
  • The absence of the wearing-off phenomenon suggests a potential advantage over levodopa-containing regimens.

Related Experiment Videos